NCT00006471View on ClinicalTrials.gov

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions
Head and Neck Cancer
Interventions
DRUG

Fenretinide

1800 mg/m2 per day for seven consecutive days, in two divided doses of 900 mg/m2 12 hours apart, repeated every 3 weeks.

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00006471 - Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Biotech Hunter | Biotech Hunter